Qinghua Huang1, Xianming Fei2, Shengbing Li3, Chan Xu4, Chunping Tu5, Lei Jiang2, Mingyi Wo2. 1. Department of Endocrinology, Zhejiang Provincial People's Hospital and People's Hospital of Hangzhou Medical College, Hangzhou 310014, China. 2. Center for Laboratory Medicine, Zhejiang Provincial People's Hospital and People's Hospital of Hangzhou Medical College, Hangzhou 310014, China. 3. Department of Laboratory Medicine, The Second Jiaxing Hospital, Jiaxing 314000, China. 4. Department of Laboratory Medicine, Zhejiang Provincial Zhongshan Hospital, Hangzhou 330106, China. 5. Department of Laboratory Medicine, Nanxun People's Hospital of Huzhou, Huzhou 313009, China.
Abstract
BACKGROUND: Cyclooxygenase-2 (COX-2) plays an important role in the monocyte-platelet aggregate (MPA)-medicated inflammatory response and possible coronary artery disease (CAD). This study aimed to assess the predicting significance of COX-2 expression in peripheral blood monocyte for CAD. METHODS: A total of 66 patients with CAD including stable angina (SA) and unstable angina (UA) were enrolled. The inflammatory indexes including white blood cell (WBC) count, high-sensitive C reactive protein (hs-CRP), serum monocyte chemoattractant protein-1 (MCP-1) and MPA levels were measured. The western-blotting assay and reverse transcription-polymerase chain reaction (RT-PCR) analysis were used to detect the COX-2 expression in peripheral blood monocytes. Furthermore, the correlation between COX-2 expression and MPA levels, and the association of COX-2 expression with CAD risk were assessed. RESULTS: The UA patients demonstrated higher levels of inflammatory indexes than the SA patients (P<0.001). Simultaneously, higher MPA levels and enhanced COX-2 expression were observed in the UA patients (P<0.01). The patients with enhanced COX-2 expression exhibited higher MPA than those without (P<0.01), and patients with increased MPA also demonstrated enhanced COX-2 expression (P<0.001). Moreover, the levels of COX-2 protein expression was positively related to the MPA formation rates (R2=0.4933, P<0.01), and enhanced COX-2 expression was independently associated with CAD risk [odds ratio (OR): 6.322, 95% confidence interval (CI): 4.544-8.978 ]. CONCLUSIONS: The COX-2 expression of peripheral blood monocytes can be used as an independent predictor for CAD. 2019 Annals of Translational Medicine. All rights reserved.
BACKGROUND: Cyclooxygenase-2 (COX-2) plays an important role in the monocyte-platelet aggregate (MPA)-medicated inflammatory response and possible coronary artery disease (CAD). This study aimed to assess the predicting significance of COX-2 expression in peripheral blood monocyte for CAD. METHODS: A total of 66 patients with CAD including stable angina (SA) and unstable angina (UA) were enrolled. The inflammatory indexes including white blood cell (WBC) count, high-sensitive C reactive protein (hs-CRP), serum monocyte chemoattractant protein-1 (MCP-1) and MPA levels were measured. The western-blotting assay and reverse transcription-polymerase chain reaction (RT-PCR) analysis were used to detect the COX-2 expression in peripheral blood monocytes. Furthermore, the correlation between COX-2 expression and MPA levels, and the association of COX-2 expression with CAD risk were assessed. RESULTS: The UA patients demonstrated higher levels of inflammatory indexes than the SA patients (P<0.001). Simultaneously, higher MPA levels and enhanced COX-2 expression were observed in the UA patients (P<0.01). The patients with enhanced COX-2 expression exhibited higher MPA than those without (P<0.01), and patients with increased MPA also demonstrated enhanced COX-2 expression (P<0.001). Moreover, the levels of COX-2 protein expression was positively related to the MPA formation rates (R2=0.4933, P<0.01), and enhanced COX-2 expression was independently associated with CAD risk [odds ratio (OR): 6.322, 95% confidence interval (CI): 4.544-8.978 ]. CONCLUSIONS: The COX-2 expression of peripheral blood monocytes can be used as an independent predictor for CAD. 2019 Annals of Translational Medicine. All rights reserved.
Authors: R Scott Wright; Jeffrey L Anderson; Cynthia D Adams; Charles R Bridges; Donald E Casey; Steven M Ettinger; Francis M Fesmire; Theodore G Ganiats; Hani Jneid; A Michael Lincoff; Eric D Peterson; George J Philippides; Pierre Theroux; Nanette K Wenger; James Patrick Zidar; Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; James Patrick Zidar Journal: J Am Coll Cardiol Date: 2011-05-10 Impact factor: 24.094
Authors: Andrew Haynes; Matthew D Linden; Elisa Robey; Louise H Naylor; Kay L Cox; Nicola T Lautenschlager; Daniel J Green Journal: Physiol Rep Date: 2017-05
Authors: Alan G Japp; Raj Chelliah; Laura Tattersall; Ninian N Lang; Xu Meng; Kathleen Weisel; Arie Katz; David Burt; Keith A A Fox; Giora Z Feuerstein; Thomas M Connolly; David E Newby Journal: J Am Heart Assoc Date: 2013-01-28 Impact factor: 5.501
Authors: Derek Strassheim; Timothy Sullivan; David C Irwin; Evgenia Gerasimovskaya; Tim Lahm; Dwight J Klemm; Edward C Dempsey; Kurt R Stenmark; Vijaya Karoor Journal: Cells Date: 2021-11-29 Impact factor: 7.666